Vivo Capital
Vivo is a global investment firm focused on healthcare with approximately $5.8 billion in AUM
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Vivo Capital Information
Geographic Data
Address: 575 High St Ste 201
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$3B
Social
Linkedin
Crunchbase
Metrics
2,761,045Website Global Rank
6,244Website Monthly Traffic
Twitter Followers
Description
The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists, entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.
Contact Phone:
+16506880818
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2020 | Elevation Oncology | Series B | 65M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 11/2007 | Ceptaris Therapeutics | Series C | 14.5M |
| 11/2015 | Celladon | Post-IPO Equity | 39.5M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 10/2018 | Terns Pharmaceuticals | Series B | 80M |
| 9/2019 | Passage Bio | Series B | 110M |
| 1/2020 | Cerebral Therapeutics | Series B | 35M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 1/2018 | Aligos Therapeutics | Series A | 100M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 4/2015 | Nabriva Therapeutics | Series B | 0 |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 11/2017 | Tricida | Series D | 0 |
| 9/2021 | Attralus | Series B | 116M |
| 3/2021 | BlossomHill Therapeutics | Series A | 71M |
| 2/2009 | Eiger BioPharmaceuticals | Series A | 8.3M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 12/2004 | Prestwick Pharmaceuticals | Series B | 37M |
| 5/2021 | Aerobiotix | Venture Round | 0 |
| 1/2010 | Neomend | Series D | 30M |
| 6/2003 | Prestwick Pharmaceuticals | Series A | 15M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 7/2019 | IGM Biosciences | Series C | 102M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 6/2009 | Sagent | Series A | 30M |
| 10/2003 | Cotherix | Series C | 55M |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 8/2007 | Prestwick Pharmaceuticals | Venture Round | 20M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 2/2007 | NextWave Pharmaceuticals | Series B | 40M |
| 4/2021 | Ronovo Surgical | Series A | - |
| 10/2020 | Gracell Biotechnologies | Series C | 0 |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 3/2019 | Cerebral Therapeutics | Series A | 7.8M |
| 5/2021 | Rgenta Therapeutics | Seed Round | 18M |
| 10/2019 | dMed | Series B | 50M |
| 3/2020 | Remegen | Private Equity Round | 0 |
| 10/2022 | Neocis | Series D | 0 |
| 10/2020 | Neocis | Series D | 72M |
| 3/2019 | MacuLogix | Series D | 0 |
| 7/2020 | Preventice Solutions | Series B | 0 |
| 8/2020 | PatientPop | Series C | 50M |
| 11/2015 | VYNE Therapeutics | Series B | 45M |
| 1/2021 | IO Biotech | Series B | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 3/2021 | Ossium Health | Series B | 63M |
| 6/2011 | Revance Therapeutics | Series D | 45M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 9/2016 | ReadCoor | Series A | 23M |
| 10/2006 | Prestwick Pharmaceuticals | Series C | 60M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 9/2018 | Immune-Onc Therapeutics | Series B | 33M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 9/2015 | Akari Therapeutics | Post-IPO Equity | 0 |
| 11/2018 | Visen Pharmaceuticals | Series A | 0 |
| 9/2008 | APT Pharmaceuticals | Series B | 32M |
| 11/2017 | Medeor Therapeutics | Series B | 0 |
| 11/2022 | Rgenta Therapeutics | Series A | 0 |
| 10/2004 | MacroGenics | Series B | 30.5M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 11/2022 | Zenas BioPharma | Series B | 0 |
| 6/2017 | Zai Lab | Series C | 30M |
| 5/2021 | Esco Lifesciences | Series A | 0 |
| 7/2020 | Citrine Medicine | Series A | 0 |
| 10/2012 | Aclaris Therapeutics | Series A | 21M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2021 | Design Therapeutics | Series B | 125M |
| 1/2020 | Aligos Therapeutics | Series B | 125M |
| 11/2022 | BioAtla | Post-IPO Equity | 0 |
| 9/2016 | SentreHEART | Series D | 35M |
| 6/2021 | RayzeBio | Series C | 108M |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 4/2020 | Legend Biotech | Series A | 0 |
| 5/2004 | CAPNIA | Series B | 12M |
| 11/2013 | Ocera Therapeutics | Post-IPO Equity | 0 |
| 5/2017 | Aadi | Series A | 23M |
| 12/2022 | Pulmocide | Series C | 0 |
| 11/2022 | Bonum | Series A | 93M |
| 2/2019 | Bolt | Series B | 54M |
| 5/2015 | REGENXBIO | Series D | 0 |
| 11/2004 | ViOptix | Series C | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 3/2017 | Angiotech Pharmaceuticals | Venture Round | - |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 12/2007 | Revance Therapeutics | Series C | 0 |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 4/2016 | Kala Pharmaceuticals | Series C | 68M |
| 10/2020 | Olema Oncology | Series C | 85M |
| 7/2020 | Tranquis Therapeutics | Series A | 30M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 10/2019 | INBRACE | Series C | 45M |
| 1/2021 | Kira Pharmaceuticals | Series B | 53.5M |
| 3/2021 | OMNI | Series D | - |
| 9/2017 | Kadmon | Post-IPO Equity | 80.4M |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 11/2012 | MEI Pharma | Post-IPO Equity | 27.5M |
| 6/2022 | Cerebral Therapeutics | Series C | 40M |
| 3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
| 12/2020 | dMed | Series C | 100M |
| 8/2022 | Klavi | Series A | 15M |
| 10/2007 | APT Pharmaceuticals | Series A | 22M |
| 8/2018 | TOT BIOPHARM | Series B | 102M |
| 12/2020 | Provivi | Series C | 0 |
| 1/2019 | Innocare | Private Equity Round | 0 |
| 3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
| 11/2007 | Carbylan Therapeutics | Series B | 20M |
| 4/2011 | Eiger BioPharmaceuticals | Series A | 14.5M |
| 6/2010 | Vicept Therapeutics | Series A | 16M |
| 5/2014 | Coherus Biosciences | Series C | 54.7M |
| 7/2018 | Sinovac Biotech | Post-IPO Equity | 86.7M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 12/2014 | Ascendis Pharma | Series D | 60M |
| 9/2018 | AirXpanders | Post-IPO Equity | 15M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 2/2021 | Innocare | Post-IPO Equity | - |
| 3/2023 | EpiBiologics | Series A | 0 |
| 9/2014 | AirXpanders | Series E | 1M |
| 4/2012 | AirXpanders | Series D | 11M |
| 1/2012 | AirXpanders | Series D | 10.3M |
| 1/2021 | Serán Bioscience | Venture Round | - |
| 9/2022 | Allakos | Post-IPO Equity | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 1/2013 | Carbylan Therapeutics | Venture Round | 6M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 4/2018 | Poseida Therapeutics | Series B | 0 |
| 8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
| 6/2012 | Ceptaris Therapeutics | Series D | 10M |
| 12/2009 | Revance Therapeutics | Series D | 0 |
| 4/2004 | Revance Therapeutics | Series B | 13M |
| 1/2021 | Visen Pharmaceuticals | Series B | 0 |
| 10/2014 | Aclaris Therapeutics | Series B | 21M |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 1/2000 | Med-eCommerce.com | Venture Round | 2M |
| 11/2002 | Copernicus Therapeutics | Venture Round | 2M |
| 9/2015 | Aclaris Therapeutics | Series C | 40M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 7/2015 | Gengmei | Series B | - |
| 5/2021 | Scientia Vascular | Private Equity Round | 50M |
| 2/2003 | AgraQuest | Venture Round | 9.4M |
| 2/2021 | ASLAN Pharmaceuticals | Post-IPO Equity | 18M |
| 1/2005 | NextWave Pharmaceuticals | Series A | 10M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 11/2011 | Medley Health | Series A | 20M |
| 8/2017 | Amyris | Post-IPO Equity | 50M |
| 6/2018 | Cerebral Therapeutics | Series A | 3M |
| 9/2007 | Sagent Pharmaceuticals | Series A | 53M |
| 2/2018 | Innocare | Private Equity Round | 55M |
| 1/2015 | Synapse Biomedical | Venture Round | - |
| 9/2008 | Sagent Pharmaceuticals | Series A | 30M |
| 11/2017 | OMNI | Series C | - |
| 7/2022 | Tebra | Series B | 0 |
| 5/2018 | MEI Pharma | Post-IPO Equity | 75M |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 8/2008 | InteKrin | Series C | 0 |
| 11/2015 | Crinetics Pharmaceuticals | Series A | 40M |
| 12/2022 | Ronovo Surgical | Series B | - |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 1/2007 | InteKrin | Series B | 0 |
| 5/2021 | Larimar Therapeutics | Post-IPO Equity | 0 |
| 7/2020 | Bolt Biotherapeutics | Series C | 93.5M |
| 11/2019 | Genetron Health | Series D | 71M |
| 3/2018 | Crinetics Pharmaceuticals | Series B | 63.5M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 6/2017 | Platelet BioGenesis | Series A | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
| 7/2016 | Tricida | Series C | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2021 | Terns Pharmaceuticals | Series C | 87M |
| 6/2013 | AirXpanders | Series E | 9M |
| 6/2012 | SentreHEART | Series C | 26M |
| 4/2021 | Sera Prognostics | Series E | 0 |
| 3/2023 | Unicycive Therapeutics | Post-IPO Equity | 0 |
| 3/2020 | Rongchang Pharmaceutical | Series A | - |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2022 | Tebra | Series B | 0 |
| 6/2022 | Cerebral Therapeutics | Series C | 0 |
| 6/2022 | DBV Technologies | Post-IPO Equity | 0 |
| 4/2022 | Visirna Therapeutics | Seed Round | 0 |
| 3/2022 | Ocelot Bio | Series A | 0 |
| 12/2021 | Avistone Pharmaceuticals | Private Equity Round | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
